Comparative Pharmacology
Head-to-head clinical analysis: DEFERIPRONE versus JADENU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERIPRONE versus JADENU.
DEFERIPRONE vs JADENU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferiprone is an iron chelator that binds to ferric iron (Fe3+) to form a stable complex, promoting iron excretion in urine. It reduces iron overload in tissues and prevents iron-induced free radical damage.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces.
75 mg/kg/day orally in three divided doses (maximum 3 g/day).
30 mg/kg once daily orally, up to a maximum of 60 mg/kg/day, for iron chelation in patients with thalassemia or other chronic iron overload; dose should be adjusted based on serum ferritin levels and therapeutic response.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium salicylate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate."
Clinical Note
moderateIron sucrose + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Deferiprone
2-3 hours (terminal elimination half-life). Due to its short half-life, multiple daily doses are required to maintain therapeutic chelation; levels decline rapidly after dose cessation.
Terminal elimination half-life is 8-16 hours (mean ~12 h) in patients with transfusional iron overload, allowing once-daily dosing.
Primarily renal excretion as iron complex (ferrioxamine) and unchanged drug; 70-90% of a dose is recovered in urine within 24 hours, predominantly as the iron chelate. Less than 10% is eliminated in feces via biliary excretion.
Primarily fecal (hepatobiliary) ~75-90% as unchanged drug and iron complex; renal excretion of deferasirox is minimal (<5% unchanged).
Category C
Category C
Iron Chelator
Iron Chelator
"The serum concentration of Deferiprone can be decreased when it is combined with Iron."